DE-Stuttgart-KLINIKUMSTUTTGART Trials

DE-Stuttgart-KLINIKUMSTUTTGART	Welcome, Profile Billing Logout

DE-Stuttgart-KLINIKUMSTUTTGART

Welcome, Profile Billing Logout

0 Trials

2 Trials

Active Trials

Export

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Schleicher, J

HOVON 156 AML, NCT04027309 / 2018-000624-33: A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy

Active, not recruiting

777

Europe, RoW

Gilteritinib, ASP2215, Midostaurin, Rydapt

Stichting Hemato-Oncologie voor Volwassenen Nederland, Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG), Astellas Pharma Global Development, Inc.

Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2

10/25

06/33

NCT06652438: Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

Recruiting

415

Europe

Revumenib, Placebo

Stichting Hemato-Oncologie voor Volwassenen Nederland, German-Austrian Acute Myeloid Leukemia Study Group, United Kingdom AML Research Network

Acute Myeloid Leukemia, Adult

12/29

07/31